Jürgen Drews

Protein Design Labs, Inc. is a biopharmaceutical company focused on the research, development and commercialization of novel therapies for inflammation and autoimmune diseases, acute cardiac conditions and cancer. PDL markets several biopharmaceutical products in the United States through its hospital sales force and wholly-owned subsidiary, ESP Pharma, Inc. As a company of development of humanized antibodies, It has licensed its patents to numerous pharmaceutical and biotechnology companies, some of which are now paying royalties on net sales of licensed products.

Genaissance Pharmaceuticals, Inc. develops and uses genetic information to diagnostic and therapeutic products. The company was founded by Kevin L. Rakin and Gualberto Ruano in 1992 and is headquartered in New Haven, CT.

Human Genome Sciences, Inc. is a biopharmaceutical company that exists to place new therapies into the hands of those battling serious disease. Its lead products include BENLYSTA for systemic lupus erythematosus and raxibacumab for inhalation anthrax. The firm's other products include, mapatumumab, darapladib, albiglutide, ZALBIN, HGS1036 and HGS1029. The company was founded by Alan G. Walton and William A. Haseltine in 1992 and is headquartered in Gaithersburg, MD.

A subsidiary of Bear Stearns Asset Management, Inc., Bear Stearns Health Innoventures Management LLC (BSHI) is a venture capital firm headquartered in New York City.

GPC Biotech AG is a biotechnology company discovering and developing new anticancer drugs.It is headquartered in Martinsried/Munich (Germany). The Company's wholly owned U.S. subsidiary has research and development sites in Waltham, Massachusetts and Princeton, New Jersey

Agennix AG was a pharmaceutical company, which engaged in the development of protein-based drugs for oncology, asthma and wound healing. Its clinical development programs included oral talactoferrin alfa and RGB-286638. The company was founded in 1993 and was headquartered in Heidelberg, Germany.